Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Tengion prices $31.4 million through private placement financing

Tengion, Inc., a leader in regenerative medicine, today announced that it has entered into definitive agreements with certain investors in connection with a PIPE financing transaction pursuant to registration exemptions under the Securities Act of 1933, as amended.

1 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Aeterna Zentaris Inc. today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.

23 Feb 2011

Canadian Cancer Society praises new, enhanced cigarette package warnings

Today, Health Canada released a set of new picture health warnings for cigarette and little cigar packages. The new labels include 16 warnings that will cover 75 per cent of the package front and back, eight additional messages to be printed inside the package (or on an insert), and four toxic emission messages for the side panel.

19 Feb 2011

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Endo Pharmaceuticals and Bioniche Life Sciences Inc. today announced plans for peer-reviewed presentation of interim efficacy and safety results from the first Phase III trial of the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™ or EN3348.

18 Feb 2011

Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

Endo Pharmaceuticals and Bioniche Life Sciences Inc., today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin.

16 Feb 2011

Positive results from Photocure's Allumera RevitAll study to improve skin's appearance

Photocure, a Norwegian specialty pharmaceutical company focused in dermatology and cancer, today announced positive results from its consumer trial with Allumera™, a breakthrough cosmetic treatment formulated to improve the skin's appearance.

4 Feb 2011

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

AndroScience Corp., based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH).

25 Jan 2011

New gene test can predict tumor spread in bladder cancer patients

Cancer scientists have designed the first molecular test to predict which bladder cancer patients may have cancer involvement in their lymph nodes at the time of surgery-which could help doctors determine which patients are good candidates for pre-surgical, or neo-adjuvant, chemotherapy.

21 Jan 2011

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

Researchers at the Johns Hopkins University School of Medicine have discovered that nitroxoline, an antibiotic commonly used around the world to treat urinary tract infections, can slow or stop the growth of human breast and bladder cancer cells by blocking the formation of new blood vessels.

20 Jan 2011

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Dendreon Corporation today announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline.

7 Jan 2011

Nippon Kayaku begins apaziquone Phase 1 bladder cancer study in Japan

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the first patient has been dosed in Japan in a Nippon Kayaku sponsored Phase 1 study of apaziquone in bladder cancer.

7 Jan 2011

Canada’s anti-smoking warnings get larger

Canada will have larger and enhanced warning labels on cigarette packs, it was revealed in a government announcement last Thursday. Health Minister Leona Aglukkaq said that these new warnings will cover three-quarters of the front and back of cigarette packs, up from one-half.

2 Jan 2011

Certain drugs may block tumor host interactions but do not destroy cancer cells

A class of drugs thought to kill cancer cells may in fact block "cross talk" between the cancer cell and normal immune cells, resulting in reduced cancer growth and spread-a discovery that could significantly alter the way cancer drugs are evaluated in the future.

23 Dec 2010

Researcher develops new method that causes cancer cells to self-destruct

Tulane University researcher W T. Godbey has developed a treatment for cancer using a method that causes cancer cells to self-destruct while sparing surrounding healthy cells.

23 Nov 2010

BioCancell raises $5.1 million by excess demand in public offering

Success for BioCancell Therapeutics Inc. Excess demand in BioCancell's public offering of shares and warrants generated immediate proceeds of $5.1 million, 18% above its stated minimal fundraising goal of $4.3 million.

23 Nov 2010

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

Bioniche Life Sciences Inc., a research-based, technology driven Canadian biopharmaceutical company, today announced achievement of a US$4.0 million milestone payment from its development partner, Endo Pharmaceuticals Inc. This milestone is the fourth achieved by Bioniche subsequent to the parties executing their agreement in July, 2009.

18 Nov 2010

BioSante announces sale of oncolytic virus technology to Cold Genesys

BioSante Pharmaceuticals, Inc., today announced it sold to Cold Genesys, Inc. exclusive, worldwide rights to develop and commercialize its oncolytic virus technology. The technology includes CG0070, a replication-competent adenovirus that has completed a Phase I clinical trial for treatment of superficial bladder cancer. In exchange for the technology, BioSante received a 19.9 percent ownership position in Cold Genesys and a $95,000 upfront cash payment and is eligible to receive future milestone and royalty payments.

18 Nov 2010

Tengion permits second patient enrollment in Neo-Urinary Conduit for bladder cancer

Tengion, Inc., a leader in regenerative medicine, announced today that the scheduled one-month, post-operative clinical assessment of the first implanted bladder cancer patient in its ongoing clinical trial has been completed as expected and has permitted the second patient to be enrolled without delay.

16 Nov 2010

Bioniche Life Sciences announces first quarter fiscal 2011 results

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of its 2011 fiscal year (ended September 30, 2010).

10 Nov 2010

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Tengion prices $31.4 million through private placement financing

TCD announces first patient treated in its TCD-717 Phase I trial

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Canadian Cancer Society praises new, enhanced cigarette package warnings

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

Positive results from Photocure's Allumera RevitAll study to improve skin's appearance

NINDS awards AndroScience $3.8M cooperative translational research grant for Kennedy's Disease

New gene test can predict tumor spread in bladder cancer patients

Researchers discover nitroxoline can reduce human breast, bladder cancer cell growth

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Nippon Kayaku begins apaziquone Phase 1 bladder cancer study in Japan

Canada’s anti-smoking warnings get larger

Certain drugs may block tumor host interactions but do not destroy cancer cells

Researcher develops new method that causes cancer cells to self-destruct

BioCancell raises $5.1 million by excess demand in public offering

Bioniche's achievement of fourth milestone in Urocidin Phase III trial triggers $4.0M payment from Endo

BioSante announces sale of oncolytic virus technology to Cold Genesys

Tengion permits second patient enrollment in Neo-Urinary Conduit for bladder cancer

Bioniche Life Sciences announces first quarter fiscal 2011 results

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Bladder Cancer News and Research

Latest Bladder Cancer News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in